Kathleen Wyne MD, PhD, FACE, FNLADirector, Adult Type 1 Diabetes Program; Director, Adult CFRD Program; Director, Diabetes Transition of Care Clinic, OSU East Hospital, Division of Endocrinology, Diabetes and Metabolism, The Ohio State University Wexner Medical Center, Columbus, Ohio
Kittie Wyne, MD, PhD, FACE, FNLA, is an adult endocrinologist specializing in the management of diabetes, lipids and hypertension. She has recently moved to The Ohio State University where she is the Director of the OSU Adult Type 1 Diabetes (T1D) Program. Dr. Wyne earned her medical degree from the Pritzker School of Medicine at the University of Chicago. After serving a residency in internal medicine at Baylor College of Medicine, Houston, Texas, she completed her fellowship in Endocrinology, Diabetes and Metabolism at the University of Texas Southwestern Medical Center, Dallas, Texas. Dr. Wyne is board certified in Endocrinology, Diabetes and Metabolism and in Clinical Lipidology. She is a Fellow of the American College of Endocrinology and of the National Lipid Association. She has just been appointed to a new term as an SGE for the US FDA on their Clinical Chemistry and Clinical Toxicology Devices Panel. Dr. Wyne has served as a member of the National Board of Directors of the American Association of Clinical Endocrinology (AACE) and the National Lipid Association (NLA) and was a member of the writing group for the 2017 AACE Lipid Guidelines. She has worked with the Texas Diabetes Council to write algorithms for the minimum standards for diabetes care in Texas and to revise their Diabetes Tool Kit, which is an educational resource for health care professionals who work with patients who have diabetes. Her interest in caring for college students with T1D has led to her involvement appointment to the Clinical Advisory Committee for the College Diabetes Network. Her current research interests are related to the role of inflammation and lipid metabolism in the etiology of diabetes. Her clinical activities are focused on management of the metabolic syndrome and on developing a center dedicated to adults with T1D. She has participated in a number of basic science and clinical research projects. Dr. Wyne has published journal articles and abstracts on her work in endocrinology, lipid metabolism, and diabetes treatment.
DisclosuresDr. Wyne reports the following:
- Research funding to OSUWMC for sponsored studies: Sanofi, Target RWE & Allergan
- Advisory Boards: Novo Nordisk & Esperion
- Speaker’s Bureau: Esperion